Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of LYL273 in Patients With Relapsed or Refractory Metastatic Colorectal Cancer

NCT05319314 is registered in ClinicalTrials.gov with Lyell Immunopharma, Inc. as lead sponsor.

NCT NCT05319314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05319314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of LYL273 in Patients With Relapsed or Refractory Metastatic Colorectal Cancer
Lead sponsor
Lyell Immunopharma, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 1, 2022
Completion date
June 30, 2032
Enrollment
155 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer